Preclinical News and Research

RSS

Natural killer cells lead the charge in cancer treatment innovation

Review synthesizes research on NK cells' role in cancer immunity and their potential in therapeutics through bioengineering, immune checkpoint inhibitors, and cell engagers, highlighting ongoing preclinical and clinical trials.

22 Feb 2024

New immunotherapy target activin receptor 1C shows promise against cancer

Drugs that target a receptor on immune cells called activin receptor 1C may combat tumor-induced immune suppression and help patients' immune systems fight back against cancer, according to a study by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

22 Feb 2024

Novel treatment for polycythemia vera shows promise in clinical trial

A novel treatment for polycythemia vera, a potentially fatal blood cancer, demonstrated the ability to control overproduction of red blood cells, the hallmark of this malignancy and many of its debilitating symptoms in a multi-center clinical trial led by the Icahn School of Medicine at Mount Sinai.

21 Feb 2024

Restoring brain pathways to fight opioid addiction

Medical University of South Carolina scientists report in Neuron that they have uncovered a way to restore an opioid-weakened brain pathway in a preclinical model.

20 Feb 2024

Novel treatment strategy shows promise against common liver cancer in children

Hepatoblastoma (HB) is the most common liver cancer in children. Researchers and physicians in the field are concerned because in the last decade HB has been rising rapidly worldwide and has seen the most rapid increase among all pediatric solid tumors.

20 Feb 2024

Study proposes novel approach to slow neuromuscular degeneration in ALS patients

A study led by the Center for Biomaterials and Tissue Engineering of the Universitat Politècnica de València, member of Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine, in collaboration with the Instituto de Investigación Sanitaria La Fe and the University of Zaragoza proposes a novel approach to slow neuromuscular degeneration in patients with Amyotrophic Lateral Sclerosis.

20 Feb 2024

Unveiling the role of CD24-Siglec10 axis in tumor immune evasion

Announcing a new article publication for BIO Integration journal. CD24, also known as heat-stable protein, is a highly glycosylated glycosylphosphatidylinositol junction membrane protein.

20 Feb 2024

Study discovers link between a breakdown product from excess niacin and heart disease

Cleveland Clinic researchers have identified a new pathway that contributes to cardiovascular disease associated with high levels of niacin, a common B vitamin previously recommended to lower cholesterol.

19 Feb 2024

Cellectricon’s expertise in pain research recognized by second EU research grant

BonePainIII project will support an early-stage researcher in quest for novel mechanistic insight and potential therapeutic targets.

From Cellectricon 19 Feb 2024

Innovative immunotherapy targets rare melanoma subtypes

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.

16 Feb 2024

City of Hope cures oldest person of blood cancer and achieves HIV remission

City of Hope, one of the largest cancer research and treatment organizations in the United States, treated the oldest person to be cured of a blood cancer and then achieve remission for HIV after receiving a blood stem cell transplant from a donor with a rare genetic mutation.

15 Feb 2024

Novel synthetic antibiotic effective against drug-resistant bacteria

A new antibiotic created by Harvard researchers overcomes antimicrobial resistance mechanisms that have rendered many modern drugs ineffective and are driving a global public health crisis.

15 Feb 2024

Neural prosthetic device successfully used to recall specific memories

A team of scientists from Wake Forest University School of Medicine and the University of Southern California (USC) have demonstrated the first successful use of a neural prosthetic device to recall specific memories.

13 Feb 2024

Glial fibrillary acidic protein levels pinpoint future dementia risk a decade in advance

Researchers identify GFAP as a potent biomarker for predicting dementia risk over a decade before clinical diagnosis, underscoring its potential for early screening and intervention in asymptomatic individuals.

13 Feb 2024

Researchers discover a molecular mechanism of noise-induced hearing loss

Anyone who has ever been to a loud concert knows the feeling of ringing ears. Some people experience temporary or even permanent hearing loss or drastic changes in their perception of sound after the loud noises stop.

12 Feb 2024

Olive oil's secret weapon against Alzheimer's: phenolic compounds

A comprehensive review in the International Journal of Molecular Sciences highlights the potential of extra-virgin olive oil and its phenolic compounds in preventing and treating Alzheimer's disease through various mechanisms, including reducing amyloid-beta accumulation and neuroinflammation.

12 Feb 2024

Promising new CMV vaccine shows stronger immune response

An experimental mRNA vaccine against human cytomegalovirus (CMV), a common virus that can infect babies during pregnancy, elicited some of the most promising immune responses to date of any CMV vaccine candidate, according to a study by Weill Cornell Medicine investigators.

12 Feb 2024

Immune system in the blood of Alzheimer's patients found to be epigenetically altered

A new Northwestern Medicine study has found the immune system in the blood of Alzheimer's patients is epigenetically altered.

9 Feb 2024

Scientists develop safer CAR T-cell strategy for treating lymphomas

In the treatment of aggressive lymphomas and blood cancer (leukaemia), so-called chimeric antigen receptor T cells (CAR T cells) are increasingly being used.

9 Feb 2024

CARB-X awards $1.8 million to Visby Medical to develop a portable rapid PCR test for gonorrhea

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award up to US$1.8 million to biotechnology company, Visby Medical, to develop a portable rapid polymerase chain reaction (PCR) diagnostic to detect the presence of the pathogen that causes gonorrhea, Neisseria gonorrhoeae (NG), and its susceptibility to ciprofloxacin, a former frontline oral antibiotic that can no longer treat resistant NG.

9 Feb 2024